Abstract
Cognitive behavioral therapy (CBT) is a first-line treatment for obsessive-compulsive disorder (OCD), but clinical response is difficult to predict. In this study, we aimed to develop predictive models using clinical and neuroimaging data from the multicenter Enhancing Neuro-Imaging and Genetics through Meta-Analysis (ENIGMA)-OCD consortium.
Baseline clinical and resting-state functional magnetic imaging (rs-fMRI) data from 159 adult patients aged 18-60 years (88 female) with OCD who received CBT at four treatment/neuroimaging sites were included. Fractional amplitude of low frequency fluctuations, regional homogeneity and atlas-based functional connectivity were computed. Clinical CBT response and remission were predicted using support vector machine and random forest classifiers on clinical data only, rs-fMRI data only, and the combination of both clinical and rs-fMRI data.
The use of only clinical data yielded an area under the ROC curve (AUC) of 0.69 for predicting remission (p=0.001). Lower baseline symptom severity, younger age, an absence of cleaning obsessions, unmedicated status, and higher education had the highest model impact in predicting remission. The best predictive performance using only rs-fMRI was obtained with regional homogeneity for remission (AUC=0.59). Predicting response with rs-fMRI generally did not exceed chance level. Machine learning models based on clinical data may thus hold promise in predicting remission after CBT for OCD, but the predictive power of multicenter rs-fMRI data is limited.
Competing Interest Statement
J.F. has received consultancy honoraria from NOCD Inc. D.S. has received consultancy honoraria from Discovery Vitality, Johnson & Johnson, Kanna, LOreal, Lundbeck, Orion, Sanofi, Servier, Takeda, and Vistagen. E.N. serves on the Scientific Advisory Board for Myriad Genetics and has received clinical trial funding from Emalex and Octapharma Pharmaceuticals. G.V.W. has received research support from Biogen, Bitbrain and Philips. The other authors reported no biomedical financial interests or potential conflict of interest. Code and data used in this work are available upon reasonable request.
Funding Statement
For full information regarding grant support to the ENIGMA-OCD Working Group, see https://enigma.ini.usc.edu/about-2/funding/. This study specifically is supported by grants awarded by the National Institute of Mental Health (NIMH; Grant No. R01MH081864; J.O. and J.C.P., R01MH085900; J.O. and J.F, R01MH129742; P.T., K23MH094613; E.N.), the National Institute on Aging Research Project (Grant No. R01AG058854; P.T.), The Western Norway Regional Health Authority (Grant. No. 911754 and 911880; A.L.T.), the South African Medical Research Council (D.S.), the Carlos III Health Institute ( Grant No. PI19/01171;C.S.M, Grant No. CM21/00278 Co Funded by the European Social fund; S.B.), the Department of Health, Generality of Catalonia (PERIS SLT006/17/249; C.S.M.); The Agency for Management of University and Research Grants (2021-SGR-01017; C.S.M.), The Maria de Maeztu Unit of Excellence, Institute of Neurosciences, University of Barcelona (CEX2021-001159-M; C.S.M) and the International OCD Foundation (Innovator Award; O.V.D.H).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Bellvitge Biomedical Research Institute (Bellvitge University Hospital) gave ethical approval for this work Ethics committee of the University of Bergen/Haukeland University Hospital Bergen gave approval of this work Ethics committee of the University of California gave approval of this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos